Experts discuss results from the targeted literature search and qualitative interviews, which identify important factors that impact their treatment decisions for patients with locally advanced/metastatic urothelial carcinoma.
Sacituzumab Govitecan Combo Shows Encouraging Responses in Bladder Cancer
February 15th 2024Investigators report clinical benefit with sacituzumab govitecan plus pembrolizumab across all prespecified patient subgroups with metastatic urothelial cancer in cohort 3 of the phase 2 TROPHY-U-01 trial.